Ocuphire Pharma Inc Ordinary Shares OCUP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if OCUP is a good fit for your portfolio.
News
-
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update
-
Ocuphire Pharma to Present in the BIO CEO & Investor Conference
-
Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Ocuphire Pharma Strengthens Leadership Team with Key Appointments
-
Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference
-
Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) Light Conditions
-
Ocuphire Shares Rally Premarket as FDA Approves Ryzumvi Eye Drops
Trading Information
- Previous Close Price
- $2.02
- Day Range
- $1.99–2.03
- 52-Week Range
- $1.85–6.60
- Bid/Ask
- $2.00 / $2.04
- Market Cap
- $49.87 Mil
- Volume/Avg
- 124,374 / 206,436
Key Statistics
- Price/Earnings (Normalized)
- 1.54
- Price/Sales
- 2.28
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting the front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 14
- Website
- https://www.ocuphire.com
Comparables
Valuation
Metric
|
OCUP
|
VRDN
|
TARS
|
---|---|---|---|
Price/Earnings (Normalized) | 1.54 | — | — |
Price/Book Value | 0.97 | 4.01 | 6.31 |
Price/Sales | 2.28 | 2,495.72 | 61.22 |
Price/Cash Flow | — | — | — |
Price/Earnings
OCUP
VRDN
TARS
Financial Strength
Metric
|
OCUP
|
VRDN
|
TARS
|
---|---|---|---|
Quick Ratio | 13.07 | 17.93 | 6.64 |
Current Ratio | 13.35 | 18.26 | 6.93 |
Interest Coverage | — | −137.76 | −44.34 |
Quick Ratio
OCUP
VRDN
TARS
Profitability
Metric
|
OCUP
|
VRDN
|
TARS
|
---|---|---|---|
Return on Assets (Normalized) | −14.73% | −42.76% | −50.11% |
Return on Equity (Normalized) | −16.08% | −82.42% | −62.96% |
Return on Invested Capital (Normalized) | −16.08% | −50.70% | −58.53% |
Return on Assets
OCUP
VRDN
TARS
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Fwhffvtfx | Zdcqg | $570.1 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Jmtppcfg | Zsghltm | $108.0 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jxxjvxp | Hchlcvx | $105.6 Bil | |
MRNA
| Moderna Inc | Vkbfxrqvk | Yfph | $40.8 Bil | |
ARGX
| argenx SE ADR | Bkwzgnpk | Qpqh | $23.5 Bil | |
BNTX
| BioNTech SE ADR | Tbgjhxq | Czdr | $21.9 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Dlmfbgsbn | Brvfqrz | $18.8 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Crgyxqhl | Wvcfkg | $16.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Bpjwjjmpdq | Ppthvg | $13.6 Bil | |
INCY
| Incyte Corp | Nrklhmmc | Xwntn | $12.8 Bil |